The Exactis Clinical Development Unit works closely with investigators to create and run complex serial biopsy trials for biomarker identification

We have the expertise and logistics to develop and manage biomarker-driven studies that involve serial metastatic tissue and liquid biopsy collection in patients before treatment, on-treatment and at the time of resistance.


Our current portfolio of in-house studies includes the following: 

Q-CROC-06 Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers NCT01949194
Q-CROC-05 Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients NCT02041468
Q-CROC-04 Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer NCT02045030
Q-CROC-03 Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients NCT01276899
Q-CROC-02 A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) NCT01238692
Q-CROC-01 Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer NCT00984048
Learn more about our Clinical Development Unit Capabilities
Learn more about our Sample Management Services

5450 Chemin de la Côte-des-Neiges

Suite 522

Montréal, Qc

H3T 1Y6


  • White LinkedIn Icon
Send Us a Message

© 2020 by Exactis Innovation